Genetic Test May Help Identify Ultra High-risk Multiple Myeloma
A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening
A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people…
FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma
Arcellx’s CART-ddBCMA — a CAR T-cell therapy targeting the BCMA protein — was granted orphan drug status by the U.S.
Gains in 5-Year Survival with Stem Cell Transplant Evident Since Late ’90s
The long-term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997…
Empliciti Combo Fails to Stem Progression of Newly Diagnosed Multiple Myeloma
Empliciti (elotuzumab), in combination with Revlimid (lenalidomide) and dexamethasone, did not significantly extend the time people with multiple myeloma…
RRMM Trial Testing Safety, Efficacy of TAK-169 Therapy Doses First Patient
The first patient has been dosed in a Phase 1 clinical trial testing the safety and efficacy of the CD38-targeting therapy TAK-169…
